NCT06407947

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Exploratory Clinical Trial of the Safety and Efficacy of CT071 Injection in Patients With High Risk Newly Diagnosed Multiple Myeloma

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Shanghai Changzheng Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma.

Detailed description

This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma (HRNDMM).

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Chimeric antigen receptor modified T cells Infusion	chimeric antigen receptor T cells

Timeline

• Start date: 2024-06-06
• Primary completion: 2027-06-03
• Completion: 2027-06-03
• First posted: 2024-05-09
• Last updated: 2024-06-12

Locations

1 site across 1 country: China